Integrated Filing — IndAS



General information about company
Scrip Code 506235
NSE Symbol ALEMBICLTD
MSEI Symbol NOTLISTED
ISIN INE426A01027
Name of company Alembic Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-Aug-2025   15:00:00
End date and time of board meeting 12-Aug-2025   15:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 497493000
Other income 35888000
Total income 533381000
2 Expenses
(a) Cost of materials consumed 34546000
(b) Purchases of stock-in-trade 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 17421000
(d) Employee benefit expense 78266000
(e) Finance costs 5933000
(f) Depreciation, depletion and amortisation expense 27919000
(f) Other Expenses
1 Cost of Construction 100996000 100996000
2 Other Expenses 70472000 70472000
Total other expenses 171468000
Total expenses 335553000
3 Total profit before exceptional items and tax 197828000
4 Exceptional items 0
5 Total profit before tax 197828000
6 Tax expense
7 Current tax 20152000
8 Deferred tax -278000
9 Total tax expenses 19874000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 177954000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 438448000
16 Total profit (loss) for period 616402000
17 Other comprehensive income net of taxes 44454000
18 Total Comprehensive Income for the period 660856000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 616402000
Total profit or loss, attributable to non-controlling interests 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 660856000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0
21 Details of equity share capital
Paid-up equity share capital 513564000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.4
Diluted earnings (loss) per share from continuing operations 2.4
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.4
Diluted earnings (loss) per share from continuing and discontinued operations 2.4
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. n n2. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. n n3. The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full finanacial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024. n n4.Figures rounded off to the nearest decimal.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Active Pharmaceutical Ingredients Business 129541000 129541000
2 Real Estate Business 367952000 367952000
Total Segment Revenue 497493000
Less: Inter segment revenue 0 0
Revenue from operations 497493000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Active Pharmaceutical Ingredients Business 27294000 27294000
2 Real Estate Business 159367000 159367000
Total Profit before tax 186661000
i. Finance cost 5933000 5933000
ii. Other Unallocable Expenditure net off Unallocable income -17100000 -17100000
Profit before tax 197828000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Active Pharmaceutical Ingredients Business 1917044000 1917044000
2 Real Estate Business 4682198000 4682198000
Total Segment Asset 6599242000 6599242000
Un-allocable Assets 18616508000 18616508000
Net Segment Asset 25215750000 25215750000
4 Segment Liabilities
Segment Liabilities
1 Active Pharmaceutical Ingredients Business 364734000 364734000
2 Real Estate Business 1085745000 1085745000
Total Segment Liabilities 1450479000 1450479000
Un-allocable Liabilities 335582000 335582000
Net Segment Liabilities 1786061000 1786061000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss 48166000 48166000
Total Amount of items that will not be reclassified to profit and loss 48166000
2 Income tax relating to items that will not be reclassified to profit or loss 6851000
3 Amount of items that will be reclassified to profit and loss
1 Amount of items that will be reclassified to profit and loss 3139000 3139000
Total Amount of items that will be reclassified to profit and loss 3139000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 44454000